Substance / Medication

Palifermin

Overview

Active Ingredient
palifermin
RxNorm CUI
196319
Labeler: Swedish Orphan Biovitrum AB (publ)Updated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy.
Coutsouvelis John, Corallo Carmela, Spencer Andrew et al. · Crit Rev Oncol Hematol · 2022
PMID: 35101586Meta-Analysis
Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin.
Yang Bing-Bing, Gillespie Brad, Smith Brian et al. · J Clin Pharmacol · 2015
PMID: 25880826RCT
Gut protection by palifermin during autologous haematopoietic SCT.
Johansson J-E, Hasséus B, Johansson P et al. · Bone Marrow Transplant · 2009
PMID: 19043460RCT
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers.
Zia-Amirhosseini Parnian, Salfi Margaret, Leese Philip et al. · Clin Pharmacol Ther · 2006
PMID: 16765144RCT
Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.
Schulz Eduard, Curtis Lauren M, Holtzman Noa G et al. · Blood · 2025
PMID: 40331908TrialFull text (PMC)
Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
Lucchese Alessandra, Matarese Giovanni, Ghislanzoni Luis Huanca et al. · Leuk Lymphoma · 2016
PMID: 26428409Trial
Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
Goldberg J D, Zheng J, Castro-Malaspina H et al. · Bone Marrow Transplant · 2013
PMID: 22750997TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Palifermin (substance)
SNOMED CT
417550009
UMLS CUI
C0677829
RxNorm CUI
196319
Labeler
Swedish Orphan Biovitrum AB (publ)

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.